| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 73 | 2020 | 1175 | 9.230 |
Why?
|
| Exercise | 47 | 2020 | 672 | 8.030 |
Why?
|
| Weight Loss | 48 | 2020 | 480 | 7.770 |
Why?
|
| Body Composition | 54 | 2019 | 397 | 5.080 |
Why?
|
| Caloric Restriction | 17 | 2020 | 106 | 4.890 |
Why?
|
| Inflammation | 27 | 2019 | 530 | 3.980 |
Why?
|
| Resistance Training | 15 | 2021 | 82 | 3.720 |
Why?
|
| Adipose Tissue | 25 | 2018 | 349 | 3.690 |
Why?
|
| Exercise Therapy | 15 | 2019 | 270 | 3.180 |
Why?
|
| Overweight | 18 | 2020 | 280 | 2.750 |
Why?
|
| Aged | 125 | 2021 | 10301 | 2.710 |
Why?
|
| Aging | 29 | 2019 | 946 | 2.710 |
Why?
|
| Postmenopause | 22 | 2015 | 430 | 2.570 |
Why?
|
| Body Mass Index | 45 | 2021 | 923 | 2.560 |
Why?
|
| Motor Activity | 12 | 2016 | 325 | 2.460 |
Why?
|
| Diet, Reducing | 13 | 2016 | 106 | 2.120 |
Why?
|
| Female | 136 | 2021 | 19959 | 2.090 |
Why?
|
| Exercise Tolerance | 11 | 2019 | 125 | 2.030 |
Why?
|
| Humans | 150 | 2021 | 32005 | 1.790 |
Why?
|
| Cytokines | 16 | 2017 | 256 | 1.720 |
Why?
|
| Muscle Strength | 14 | 2019 | 161 | 1.670 |
Why?
|
| Osteoarthritis, Knee | 11 | 2021 | 90 | 1.630 |
Why?
|
| Male | 106 | 2021 | 19165 | 1.590 |
Why?
|
| Interleukin-6 | 20 | 2016 | 247 | 1.560 |
Why?
|
| Physical Fitness | 10 | 2019 | 131 | 1.520 |
Why?
|
| Oxygen Consumption | 13 | 2019 | 154 | 1.500 |
Why?
|
| Adiponectin | 8 | 2015 | 106 | 1.490 |
Why?
|
| Muscle, Skeletal | 18 | 2019 | 519 | 1.460 |
Why?
|
| Middle Aged | 69 | 2021 | 11817 | 1.370 |
Why?
|
| Heart Failure | 8 | 2018 | 639 | 1.300 |
Why?
|
| C-Reactive Protein | 16 | 2017 | 238 | 1.250 |
Why?
|
| Life Style | 10 | 2020 | 408 | 1.160 |
Why?
|
| Abdominal Fat | 8 | 2018 | 50 | 1.150 |
Why?
|
| Gait | 9 | 2020 | 142 | 1.150 |
Why?
|
| Inflammation Mediators | 6 | 2012 | 104 | 1.110 |
Why?
|
| Weight Gain | 4 | 2019 | 117 | 1.100 |
Why?
|
| Energy Metabolism | 7 | 2016 | 147 | 1.090 |
Why?
|
| Diet | 8 | 2020 | 391 | 1.090 |
Why?
|
| Adiposity | 8 | 2018 | 198 | 1.030 |
Why?
|
| Absorptiometry, Photon | 16 | 2019 | 143 | 1.030 |
Why?
|
| Exercise Test | 8 | 2019 | 227 | 1.010 |
Why?
|
| Cardiovascular Diseases | 10 | 2019 | 1128 | 0.990 |
Why?
|
| Follow-Up Studies | 23 | 2021 | 2265 | 0.980 |
Why?
|
| Geriatric Assessment | 10 | 2019 | 390 | 0.940 |
Why?
|
| Mobility Limitation | 10 | 2019 | 219 | 0.880 |
Why?
|
| Fatigue | 3 | 2019 | 85 | 0.860 |
Why?
|
| Adipokines | 5 | 2011 | 16 | 0.860 |
Why?
|
| Bone Density | 6 | 2019 | 205 | 0.840 |
Why?
|
| Knee Joint | 5 | 2021 | 142 | 0.830 |
Why?
|
| Aged, 80 and over | 32 | 2020 | 3990 | 0.830 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 510 | 0.750 |
Why?
|
| Blood Glucose | 12 | 2019 | 494 | 0.690 |
Why?
|
| Body Fat Distribution | 7 | 2018 | 34 | 0.680 |
Why?
|
| Single-Blind Method | 11 | 2021 | 203 | 0.680 |
Why?
|
| Stroke Volume | 7 | 2018 | 348 | 0.670 |
Why?
|
| Obesity, Morbid | 3 | 2016 | 73 | 0.670 |
Why?
|
| Subcutaneous Fat | 4 | 2015 | 47 | 0.670 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 22 | 0.630 |
Why?
|
| Leptin | 5 | 2014 | 71 | 0.630 |
Why?
|
| MicroRNAs | 2 | 2017 | 180 | 0.590 |
Why?
|
| Insulin | 10 | 2012 | 367 | 0.580 |
Why?
|
| Cholesterol, HDL | 9 | 2015 | 177 | 0.570 |
Why?
|
| Mortality | 2 | 2015 | 125 | 0.550 |
Why?
|
| Energy Intake | 5 | 2014 | 128 | 0.510 |
Why?
|
| Chronic Disease | 8 | 2017 | 406 | 0.510 |
Why?
|
| Walking | 12 | 2020 | 209 | 0.500 |
Why?
|
| Obesity, Abdominal | 2 | 2014 | 24 | 0.490 |
Why?
|
| Lipids | 4 | 2015 | 232 | 0.490 |
Why?
|
| Risk Reduction Behavior | 2 | 2017 | 125 | 0.490 |
Why?
|
| Gene Expression Regulation | 5 | 2015 | 495 | 0.480 |
Why?
|
| Quadriceps Muscle | 3 | 2016 | 34 | 0.470 |
Why?
|
| Risk Factors | 21 | 2020 | 3876 | 0.470 |
Why?
|
| Body Weight | 9 | 2019 | 310 | 0.460 |
Why?
|
| European Continental Ancestry Group | 10 | 2017 | 1166 | 0.450 |
Why?
|
| Coronary Disease | 3 | 2006 | 211 | 0.450 |
Why?
|
| Quality of Life | 3 | 2016 | 946 | 0.450 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2010 | 210 | 0.440 |
Why?
|
| Disability Evaluation | 6 | 2019 | 240 | 0.440 |
Why?
|
| African Continental Ancestry Group | 7 | 2017 | 363 | 0.440 |
Why?
|
| Uric Acid | 1 | 2013 | 27 | 0.420 |
Why?
|
| Time Factors | 7 | 2018 | 2149 | 0.420 |
Why?
|
| Atherosclerosis | 1 | 2018 | 766 | 0.410 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2010 | 46 | 0.400 |
Why?
|
| Treatment Outcome | 11 | 2019 | 3306 | 0.390 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2020 | 1428 | 0.380 |
Why?
|
| Dietary Proteins | 2 | 2008 | 55 | 0.380 |
Why?
|
| Tumor Necrosis Factors | 1 | 2010 | 5 | 0.380 |
Why?
|
| Muscle Fibers, Skeletal | 3 | 2019 | 109 | 0.370 |
Why?
|
| Pericardium | 1 | 2011 | 52 | 0.370 |
Why?
|
| Interleukins | 1 | 2010 | 19 | 0.370 |
Why?
|
| Viscera | 3 | 2004 | 17 | 0.360 |
Why?
|
| Lipolysis | 4 | 2006 | 18 | 0.360 |
Why?
|
| Health Education | 4 | 2019 | 157 | 0.360 |
Why?
|
| Regression Analysis | 8 | 2014 | 293 | 0.360 |
Why?
|
| Muscle Weakness | 1 | 2010 | 37 | 0.350 |
Why?
|
| Capillaries | 2 | 2014 | 24 | 0.350 |
Why?
|
| Cross-Sectional Studies | 9 | 2019 | 1531 | 0.340 |
Why?
|
| Adipocytes | 5 | 2017 | 81 | 0.340 |
Why?
|
| Combined Modality Therapy | 7 | 2016 | 560 | 0.340 |
Why?
|
| Comorbidity | 2 | 2019 | 566 | 0.320 |
Why?
|
| Prospective Studies | 16 | 2019 | 2282 | 0.320 |
Why?
|
| Health Behavior | 2 | 2013 | 232 | 0.320 |
Why?
|
| Cholesterol, LDL | 7 | 2015 | 173 | 0.300 |
Why?
|
| Knee | 1 | 2007 | 33 | 0.290 |
Why?
|
| Pilot Projects | 4 | 2019 | 545 | 0.290 |
Why?
|
| Insulin Resistance | 6 | 2017 | 462 | 0.280 |
Why?
|
| Health Status | 7 | 2016 | 399 | 0.280 |
Why?
|
| Hand Strength | 5 | 2016 | 101 | 0.270 |
Why?
|
| Thigh | 5 | 2018 | 42 | 0.260 |
Why?
|
| Prognosis | 7 | 2019 | 1497 | 0.260 |
Why?
|
| Mitochondria, Muscle | 2 | 2016 | 18 | 0.260 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 881 | 0.250 |
Why?
|
| Lipoproteins | 2 | 2003 | 86 | 0.250 |
Why?
|
| Polymorphism, Genetic | 4 | 2014 | 184 | 0.250 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 56 | 0.240 |
Why?
|
| Cholesterol | 4 | 2015 | 252 | 0.240 |
Why?
|
| Physical Education and Training | 1 | 2004 | 13 | 0.230 |
Why?
|
| Weight-Bearing | 3 | 2014 | 40 | 0.230 |
Why?
|
| Myocardial Infarction | 2 | 2006 | 475 | 0.230 |
Why?
|
| Independent Living | 2 | 2015 | 99 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 1328 | 0.220 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 145 | 0.220 |
Why?
|
| Linear Models | 7 | 2019 | 447 | 0.220 |
Why?
|
| Climacteric | 1 | 2002 | 6 | 0.220 |
Why?
|
| Thiazolidinediones | 3 | 2013 | 47 | 0.210 |
Why?
|
| Prevalence | 5 | 2015 | 981 | 0.210 |
Why?
|
| Triglycerides | 5 | 2015 | 230 | 0.210 |
Why?
|
| Activities of Daily Living | 6 | 2009 | 257 | 0.210 |
Why?
|
| Muscle Contraction | 3 | 2019 | 114 | 0.210 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3509 | 0.200 |
Why?
|
| Apolipoproteins E | 1 | 2002 | 95 | 0.200 |
Why?
|
| Diet, Fat-Restricted | 1 | 2002 | 31 | 0.200 |
Why?
|
| Hypoglycemic Agents | 3 | 2013 | 181 | 0.200 |
Why?
|
| Case-Control Studies | 7 | 2019 | 898 | 0.190 |
Why?
|
| Continental Population Groups | 2 | 2020 | 237 | 0.190 |
Why?
|
| Blood Pressure | 4 | 2015 | 845 | 0.190 |
Why?
|
| Basal Metabolism | 3 | 2008 | 9 | 0.190 |
Why?
|
| Models, Biological | 3 | 2015 | 392 | 0.190 |
Why?
|
| Cohort Studies | 8 | 2013 | 1817 | 0.190 |
Why?
|
| Pain Measurement | 5 | 2021 | 350 | 0.180 |
Why?
|
| Appetite | 1 | 2020 | 22 | 0.180 |
Why?
|
| Glucose Tolerance Test | 5 | 2009 | 126 | 0.180 |
Why?
|
| Body Constitution | 4 | 2004 | 25 | 0.180 |
Why?
|
| Age Factors | 7 | 2019 | 1188 | 0.180 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 4 | 2009 | 44 | 0.170 |
Why?
|
| Gastric Bypass | 2 | 2011 | 32 | 0.170 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 100 | 0.170 |
Why?
|
| Femur Neck | 2 | 2017 | 21 | 0.170 |
Why?
|
| Cough | 1 | 2019 | 19 | 0.170 |
Why?
|
| Dyspnea | 1 | 2019 | 33 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2014 | 132 | 0.170 |
Why?
|
| Abdomen | 6 | 2004 | 43 | 0.170 |
Why?
|
| Executive Function | 1 | 2019 | 57 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2018 | 918 | 0.160 |
Why?
|
| Incidence | 6 | 2011 | 1199 | 0.160 |
Why?
|
| Random Allocation | 1 | 2019 | 226 | 0.160 |
Why?
|
| North Carolina | 5 | 2015 | 1514 | 0.160 |
Why?
|
| Behavior Therapy | 2 | 2016 | 103 | 0.160 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 411 | 0.150 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 371 | 0.150 |
Why?
|
| Frail Elderly | 1 | 2018 | 68 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2018 | 94 | 0.150 |
Why?
|
| United States | 7 | 2017 | 3939 | 0.150 |
Why?
|
| Lipoproteins, LDL | 2 | 2009 | 81 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2016 | 225 | 0.140 |
Why?
|
| Heart | 1 | 2018 | 177 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 684 | 0.140 |
Why?
|
| Fatty Acids | 2 | 2015 | 98 | 0.140 |
Why?
|
| Proportional Hazards Models | 6 | 2011 | 753 | 0.140 |
Why?
|
| Smoking | 2 | 2019 | 497 | 0.140 |
Why?
|
| Arthritis | 1 | 2017 | 40 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 9 | 0.140 |
Why?
|
| Adult | 11 | 2016 | 9345 | 0.140 |
Why?
|
| Troponin T | 2 | 2015 | 81 | 0.140 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 2016 | 52 | 0.130 |
Why?
|
| Probability | 2 | 2009 | 158 | 0.130 |
Why?
|
| Pain | 3 | 2021 | 288 | 0.130 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 64 | 0.130 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2015 | 8 | 0.130 |
Why?
|
| Intra-Abdominal Fat | 3 | 2018 | 63 | 0.130 |
Why?
|
| Respiration, Artificial | 1 | 2016 | 98 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 66 | 0.130 |
Why?
|
| Alleles | 3 | 2006 | 248 | 0.130 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2013 | 13 | 0.130 |
Why?
|
| Osteocalcin | 1 | 2015 | 9 | 0.130 |
Why?
|
| Publication Bias | 1 | 2015 | 8 | 0.130 |
Why?
|
| Yoga | 1 | 2016 | 50 | 0.130 |
Why?
|
| Leukocyte Count | 2 | 2015 | 49 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2012 | 1426 | 0.120 |
Why?
|
| Cognition | 1 | 2019 | 555 | 0.120 |
Why?
|
| Migraine Disorders | 1 | 2015 | 67 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2015 | 66 | 0.120 |
Why?
|
| Length of Stay | 1 | 2016 | 314 | 0.120 |
Why?
|
| Glucose Clamp Technique | 5 | 2008 | 12 | 0.120 |
Why?
|
| Thinness | 2 | 2011 | 33 | 0.120 |
Why?
|
| Osteoporosis | 2 | 2019 | 70 | 0.120 |
Why?
|
| Fasting | 3 | 2003 | 95 | 0.120 |
Why?
|
| RNA, Messenger | 2 | 2013 | 508 | 0.120 |
Why?
|
| Waist-Hip Ratio | 2 | 2011 | 34 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2011 | 876 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 215 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 55 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2004 | 105 | 0.110 |
Why?
|
| Brain | 1 | 2020 | 951 | 0.110 |
Why?
|
| Body Weights and Measures | 1 | 2013 | 24 | 0.110 |
Why?
|
| Hypertension | 3 | 2011 | 959 | 0.110 |
Why?
|
| Bacterial Translocation | 1 | 2012 | 9 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 10 | 0.110 |
Why?
|
| Acceleration | 2 | 2019 | 65 | 0.110 |
Why?
|
| Longitudinal Studies | 5 | 2019 | 767 | 0.110 |
Why?
|
| Sex Factors | 4 | 2019 | 663 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 73 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 9 | 0.100 |
Why?
|
| Platelet Activation | 1 | 2012 | 13 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2013 | 463 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 101 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 77 | 0.100 |
Why?
|
| Animals | 5 | 2017 | 7541 | 0.100 |
Why?
|
| Muscular Atrophy | 2 | 2012 | 71 | 0.100 |
Why?
|
| Body Fluid Compartments | 1 | 2011 | 5 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2012 | 136 | 0.100 |
Why?
|
| Genotype | 4 | 2014 | 733 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2011 | 63 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 582 | 0.100 |
Why?
|
| Fibrinogen | 1 | 2011 | 44 | 0.090 |
Why?
|
| Lipid Peroxidation | 2 | 2012 | 33 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2008 | 153 | 0.090 |
Why?
|
| Testosterone | 2 | 2007 | 48 | 0.090 |
Why?
|
| Pennsylvania | 3 | 2004 | 83 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2012 | 231 | 0.090 |
Why?
|
| Tennessee | 3 | 2004 | 102 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 89 | 0.090 |
Why?
|
| Bicycling | 1 | 2009 | 14 | 0.090 |
Why?
|
| Cardiac Output | 1 | 2009 | 36 | 0.090 |
Why?
|
| Nutrition Policy | 1 | 2009 | 35 | 0.090 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2009 | 12 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 184 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 633 | 0.080 |
Why?
|
| Diabetes Complications | 2 | 2015 | 177 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2019 | 149 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2009 | 93 | 0.080 |
Why?
|
| Glucose | 2 | 2008 | 174 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2009 | 100 | 0.080 |
Why?
|
| African Americans | 3 | 2015 | 1425 | 0.080 |
Why?
|
| Aorta | 1 | 2009 | 126 | 0.080 |
Why?
|
| Gene Frequency | 2 | 2014 | 220 | 0.080 |
Why?
|
| Age Distribution | 2 | 2009 | 206 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2009 | 199 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 217 | 0.080 |
Why?
|
| Dementia | 1 | 2011 | 252 | 0.080 |
Why?
|
| Arthralgia | 1 | 2008 | 33 | 0.080 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2007 | 34 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2011 | 385 | 0.070 |
Why?
|
| Research Design | 1 | 2009 | 313 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 762 | 0.070 |
Why?
|
| Serum Amyloid A Protein | 1 | 2006 | 5 | 0.070 |
Why?
|
| Haplotypes | 1 | 2006 | 220 | 0.070 |
Why?
|
| Kidney | 1 | 2010 | 518 | 0.070 |
Why?
|
| Logistic Models | 4 | 2012 | 781 | 0.070 |
Why?
|
| Weight Lifting | 1 | 2005 | 10 | 0.070 |
Why?
|
| Muscle Fibers, Slow-Twitch | 2 | 2015 | 20 | 0.070 |
Why?
|
| Locomotion | 1 | 2005 | 31 | 0.060 |
Why?
|
| Muscle Fibers, Fast-Twitch | 2 | 2015 | 30 | 0.060 |
Why?
|
| Cell Respiration | 2 | 2015 | 22 | 0.060 |
Why?
|
| Urban Health | 1 | 2004 | 15 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2004 | 41 | 0.060 |
Why?
|
| Hyperinsulinism | 1 | 2004 | 13 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2005 | 244 | 0.060 |
Why?
|
| Lipoprotein Lipase | 1 | 2004 | 14 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2004 | 70 | 0.060 |
Why?
|
| Depression | 1 | 2007 | 444 | 0.060 |
Why?
|
| Postprandial Period | 1 | 2003 | 10 | 0.060 |
Why?
|
| Anaerobic Threshold | 1 | 2003 | 5 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 835 | 0.050 |
Why?
|
| Blood Chemical Analysis | 1 | 2003 | 22 | 0.050 |
Why?
|
| Heart Rate | 2 | 2017 | 335 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2003 | 100 | 0.050 |
Why?
|
| Proteins | 1 | 2003 | 144 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 109 | 0.050 |
Why?
|
| Apolipoprotein E4 | 1 | 2002 | 63 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 1022 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2002 | 110 | 0.050 |
Why?
|
| Menopause | 1 | 2002 | 95 | 0.050 |
Why?
|
| Stroke | 1 | 2006 | 585 | 0.050 |
Why?
|
| Compressive Strength | 1 | 2021 | 23 | 0.050 |
Why?
|
| Cause of Death | 2 | 2012 | 236 | 0.050 |
Why?
|
| Sarcopenia | 2 | 2012 | 64 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2002 | 199 | 0.050 |
Why?
|
| Counseling | 1 | 2020 | 97 | 0.040 |
Why?
|
| Accidental Falls | 2 | 2012 | 222 | 0.040 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2018 | 15 | 0.040 |
Why?
|
| Health | 2 | 2009 | 14 | 0.040 |
Why?
|
| Receptors, Cytokine | 2 | 2009 | 8 | 0.040 |
Why?
|
| Lysine | 1 | 2017 | 23 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 130 | 0.040 |
Why?
|
| Citrate (si)-Synthase | 1 | 2016 | 3 | 0.030 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Stearic Acids | 1 | 2015 | 5 | 0.030 |
Why?
|
| Linoleic Acid | 1 | 2015 | 16 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2015 | 35 | 0.030 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2015 | 8 | 0.030 |
Why?
|
| Torque | 1 | 2015 | 20 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 36 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2016 | 110 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 35 | 0.030 |
Why?
|
| Vitamin K 1 | 1 | 2015 | 11 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 39 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 90 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 117 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 2007 | 173 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 208 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 188 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2015 | 30 | 0.030 |
Why?
|
| Patellofemoral Joint | 1 | 2014 | 15 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2014 | 92 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 240 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2013 | 8 | 0.030 |
Why?
|
| Microcirculation | 1 | 2014 | 65 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2014 | 45 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2013 | 26 | 0.030 |
Why?
|
| Movement Disorders | 1 | 2013 | 26 | 0.030 |
Why?
|
| Isoproterenol | 2 | 2004 | 16 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 198 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2014 | 175 | 0.030 |
Why?
|
| Muscle Development | 1 | 2013 | 49 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2013 | 16 | 0.030 |
Why?
|
| Isotonic Contraction | 1 | 2012 | 8 | 0.030 |
Why?
|
| Myofibrils | 1 | 2012 | 8 | 0.030 |
Why?
|
| Biopsy | 1 | 2013 | 259 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2012 | 32 | 0.030 |
Why?
|
| ROC Curve | 1 | 2012 | 164 | 0.030 |
Why?
|
| Thromboxane B2 | 1 | 2012 | 6 | 0.030 |
Why?
|
| Dinoprost | 1 | 2012 | 10 | 0.030 |
Why?
|
| Myosin Heavy Chains | 1 | 2012 | 89 | 0.030 |
Why?
|
| Distance Perception | 1 | 2011 | 3 | 0.020 |
Why?
|
| Judgment | 1 | 2011 | 11 | 0.020 |
Why?
|
| Intention | 1 | 2011 | 28 | 0.020 |
Why?
|
| Arm | 1 | 2011 | 35 | 0.020 |
Why?
|
| Choristoma | 1 | 2011 | 17 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 321 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 97 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2011 | 46 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 105 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 608 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 218 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 99 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 86 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2009 | 50 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2009 | 49 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2009 | 75 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 297 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2009 | 30 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2014 | 605 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 85 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2009 | 77 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 472 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2008 | 53 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2009 | 101 | 0.020 |
Why?
|
| Meat | 1 | 2008 | 15 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2009 | 245 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 376 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2008 | 55 | 0.020 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2007 | 8 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 352 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 34 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2008 | 172 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2006 | 84 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2005 | 108 | 0.020 |
Why?
|
| Cell Line | 1 | 2006 | 435 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 246 | 0.020 |
Why?
|
| Solubility | 1 | 2004 | 36 | 0.020 |
Why?
|
| Serum | 1 | 2004 | 19 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2005 | 187 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 137 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 483 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 301 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2004 | 10 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2004 | 30 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2003 | 7 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 8 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2003 | 3 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2003 | 16 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2003 | 8 | 0.010 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2003 | 4 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 767 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2003 | 24 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2003 | 48 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 38 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2003 | 124 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 2003 | 68 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2003 | 103 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2003 | 80 | 0.010 |
Why?
|
| Bucladesine | 1 | 2002 | 7 | 0.010 |
Why?
|
| Progesterone | 1 | 2002 | 101 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 632 | 0.010 |
Why?
|
| Estrogens | 1 | 2002 | 180 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 2484 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 3539 | 0.010 |
Why?
|